NexImmune (NEXI) Stock Highlights

0.82 | -29.91%

2024-08-14 06:03:48

NexImmune Inc is a clinical-stage biotechnology company engaged in developing immunotherapy to employ the bodys T cells to generate an immune response that mimics natural biology. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.

Statistics

Range Today

0.82 1.18

Volume Today 8.5K

Range 1 Year

0.98 28.69

Volume 1 Year 194.16M

Range 3 Year

0.98 469.5

Volume 3 Year 204.34M

Range 10 Year

0.98 700

Volume 10 Year 204.81M

Highlights

Market Capitalization 1.59M (micro)

Floating Shares 1.15M

Current Price 0.82

Price To Earnings -0.04

Price To Book 0.35

Earnings Per Share -26.43

Payout Ratio 0%

Performance

Latest -29.91%

1 Month -69.63%

3 Months -76.57%

6 Months -91.58%

1 Year -86.88%

3 Years -99.74%

5 Years -99.86%

10 Years -99.86%

Benchmarks

Market Capitalization

0 / 368

Gross Profits

0 / 278

Total Revenue

0 / 300

Total Rank

0 / 368

Free Cashflow

0 / 352

Performance 5 years

0 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.